133 related articles for article (PubMed ID: 31902599)
1. The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy.
Sastre L; García-López M; Pérez-Del-Pulgar S; Lens S; Costa J; Navasa M; Forns X
Gastroenterol Hepatol; 2020 Mar; 43(3):136-137. PubMed ID: 31902599
[No Abstract] [Full Text] [Related]
2. Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient.
Drinane M; Jing Wang X; Watt K
Hepatology; 2019 May; 69(5):2297-2299. PubMed ID: 30549275
[No Abstract] [Full Text] [Related]
3. Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
Fraga M; Gouttenoire J; Sahli R; Chtioui H; Marcu C; Pascual M; Moradpour D; Vionnet J
BMC Gastroenterol; 2019 May; 19(1):76. PubMed ID: 31126238
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
van der Valk M; Zaaijer HL; Kater AP; Schinkel J
J Hepatol; 2017 Jan; 66(1):242-243. PubMed ID: 27702641
[No Abstract] [Full Text] [Related]
6. Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection.
Marion O; Abravanel F; Izopet J; Kamar N
Transpl Infect Dis; 2019 Apr; 21(2):e13050. PubMed ID: 30663838
[No Abstract] [Full Text] [Related]
7. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
8. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Saab S; Jimenez M; Bau S; Goo T; Zhao D; Durazo F; Han S; El Kabany M; Kaldas F; Tong MJ; Busuttil RW
Clin Transplant; 2015 Sep; 29(9):813-9. PubMed ID: 26147216
[TBL] [Abstract][Full Text] [Related]
9. [Chronic hepatitis caused by hepatitis E virus and treated with ribavirin].
Mora Soler AM; Velasco-Guardado A; Martín Arribas MI; Acosta Materan R; Revilla Morato C; Pérez Corte D; Rodríguez Pérez A
Gastroenterol Hepatol; 2016 Nov; 39(9):597-598. PubMed ID: 26589539
[No Abstract] [Full Text] [Related]
10. Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Tang L; Ward H; Kattakuzhy S; Wilson E; Kottilil S
Expert Rev Gastroenterol Hepatol; 2016; 10(1):21-36. PubMed ID: 26558305
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
13. Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin.
Biliotti E; Franchi C; Spaziante M; Garbuglia AR; Volpicelli L; Palazzo D; De Angelis M; Esvan R; Taliani G
Infection; 2018 Oct; 46(5):725-727. PubMed ID: 29946850
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
[TBL] [Abstract][Full Text] [Related]
15. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.
von Felden J; Alric L; Pischke S; Aitken C; Schlabe S; Spengler U; Giordani MT; Schnitzler P; Bettinger D; Thimme R; Xhaard A; Binder M; Ayuk F; Lohse AW; Cornelissen JJ; de Man RA; Mallet V
J Hepatol; 2019 Sep; 71(3):465-472. PubMed ID: 31108159
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U
Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
19. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
20. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
